Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Fig. 2

Overall efficiency for additional Capecitabine use in early-staged TNBC. A summarized HR for OS in whole TNBC patients, all RCTs included; (B) summarized HR for DFS in whole TNBC patients, all RCTs included; (C) summarized HR for OS in unselected TNBC patients, with CREATE-X excluded; (D) summarized HR for DFS in unselected TNBC patients, with CREATE-X excluded

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us